Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:14 PM
Ignite Modification Date:
2025-12-24 @ 5:14 PM
NCT ID:
NCT07266350
Eligibility Criteria:
Inclusion Criteria:
1. Age ≥18 years old;
2. Sign the informed consent form and voluntarily join this study;
3. Patients with cervical cancer diagnosed by histopathology;
4. Receive treatment with monotherapy or combination regimens based on camrelizumab or famitinib;
5. It is necessary to agree to take effective contraceptive measures and avoid egg donation from the time of signing the informed consent form until 2 months after the last administration of camrelizumab, 3 months after the last administration of famitinib, or within the contraceptive period specified in the instructions of the last administration of other study drugs (whichever is longer).
If a patient has had menstruation but has not yet reached postmenopausal status (with no menstruation for a continuous period of ≥12 months and no other causes found except menopause), and has not undergone sterilization surgery (such as hysterectomy, bilateral tubal ligation or bilateral oophorectomy), the patient is considered to have fertility.
Exclusion Criteria:
1. There is already evidence indicating that the patient is a pregnant or lactating woman.
2. Currently participating in any research involving intervention measures outside of regular clinical practice;
3. The researcher determines other circumstances that are not suitable for inclusion in the study.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT07266350
Study Brief:
Protocol Section:
NCT07266350